Evogene (EVGN) Non-Current Assets (2016 - 2025)
Evogene (EVGN) posted Non-Current Assets of $4.4 million for Q4 2025, down 16.4% sequentially from $5.3 million in Q2 2025, and down 75.84% YoY from $18.3 million in Q4 2024.
Evogene (EVGN) Non-Current Assets (2016 - 2025) Analysis & Trends
Evogene has reported Non-Current Assets for 10 years, with the latest figure at $4.4 million in Q4 2025.
- Quarterly Non-Current Assets fell 75.84% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.2 million (down 36.26% YoY) and the FY2025 annual result came in at $4.4 million, down 75.84% from the prior year.
- Non-Current Assets fell to $4.4 million in Q4 2025 per EVGN's latest filing, from $5.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $19.7 million in Q2 2021 and troughed at $4.4 million in Q4 2025.
- A 5-year average of $15.4 million and a median of $17.9 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets grew 9.88% in 2024, then tumbled 75.84% in 2025.
- Over 5 years, Non-Current Assets stood at $19.4 million in 2021, then decreased by 5.35% to $18.4 million in 2022, then decreased by 9.49% to $16.6 million in 2023, then rose by 9.88% to $18.3 million in 2024, then plunged by 75.84% to $4.4 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $4.4 million, $5.3 million, and $18.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.42 Mn |
| Jun 30, 2025 | 5.28 Mn |
| Dec 31, 2024 | 18.28 Mn |
| Jun 30, 2024 | 15.19 Mn |
| Dec 31, 2023 | 16.63 Mn |
| Jun 30, 2023 | 17.62 Mn |
| Dec 31, 2022 | 18.38 Mn |
| Jun 30, 2022 | 18.96 Mn |
| Dec 31, 2021 | 19.41 Mn |
| Jun 30, 2021 | 19.67 Mn |
| Dec 31, 2020 | 20.09 Mn |
| Jun 30, 2020 | 21.26 Mn |
| Dec 31, 2019 | 22.34 Mn |
| Dec 31, 2018 | 3.21 Mn |
| Dec 31, 2017 | 4.81 Mn |
| Dec 31, 2016 | 6.50 Mn |